284 related articles for article (PubMed ID: 36482393)
1. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Fooks K; Galicia-Vazquez G; Gife V; Schcolnik-Cabrera A; Nouhi Z; Poon WWL; Luo V; Rys RN; Aloyz R; Orthwein A; Johnson NA; Hulea L; Mercier FE
J Exp Clin Cancer Res; 2022 Dec; 41(1):340. PubMed ID: 36482393
[TBL] [Abstract][Full Text] [Related]
2. Targeted inhibition of eIF4A suppresses B-cell receptor-induced translation and expression of MYC and MCL1 in chronic lymphocytic leukemia cells.
Wilmore S; Rogers-Broadway KR; Taylor J; Lemm E; Fell R; Stevenson FK; Forconi F; Steele AJ; Coldwell M; Packham G; Yeomans A
Cell Mol Life Sci; 2021 Sep; 78(17-18):6337-6349. PubMed ID: 34398253
[TBL] [Abstract][Full Text] [Related]
3. Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.
Gaur T; Poddutoori R; Khare L; Bagal B; Rashmi S; Patkar N; Tembhare P; Pg S; Shetty D; Dutt A; Zhang Q; Konopleva M; Platzbeckar U; Gupta S; Samajdar S; Ramchandra M; Khattry N; Hasan SK
J Exp Clin Cancer Res; 2023 Jul; 42(1):186. PubMed ID: 37507802
[TBL] [Abstract][Full Text] [Related]
4. Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia.
Seipel K; Brügger Y; Mandhair H; Bacher U; Pabst T
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293442
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.
Nishida Y; Zhao R; Heese LE; Akiyama H; Patel S; Jaeger AM; Jacamo RO; Kojima K; Ma MCJ; Ruvolo VR; Chachad D; Devine W; Lindquist S; Davis RE; Porco JA; Whitesell L; Andreeff M; Ishizawa J
Leukemia; 2021 Sep; 35(9):2469-2481. PubMed ID: 34127794
[TBL] [Abstract][Full Text] [Related]
6. Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Liu F; Zhao Q; Su Y; Lv J; Gai Y; Liu S; Lin H; Wang Y; Wang G
Exp Hematol; 2022 Jan; 105():39-49. PubMed ID: 34767916
[TBL] [Abstract][Full Text] [Related]
7. Targeting Myeloperoxidase Disrupts Mitochondrial Redox Balance and Overcomes Cytarabine Resistance in Human Acute Myeloid Leukemia.
Hosseini M; Rezvani HR; Aroua N; Bosc C; Farge T; Saland E; Guyonnet-Dupérat V; Zaghdoudi S; Jarrou L; Larrue C; Sabatier M; Mouchel PL; Gotanègre M; Piechaczyk M; Bossis G; Récher C; Sarry JE
Cancer Res; 2019 Oct; 79(20):5191-5203. PubMed ID: 31358527
[TBL] [Abstract][Full Text] [Related]
8. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia.
Ramsey HE; Fischer MA; Lee T; Gorska AE; Arrate MP; Fuller L; Boyd KL; Strickland SA; Sensintaffar J; Hogdal LJ; Ayers GD; Olejniczak ET; Fesik SW; Savona MR
Cancer Discov; 2018 Dec; 8(12):1566-1581. PubMed ID: 30185627
[TBL] [Abstract][Full Text] [Related]
9. Oridonin Synergistically Enhances the Pro-Apoptotic Effect of Venetoclax on Acute Myeloid Leukemia Cells by Inhibiting AKT Signaling.
Chen L; Li D; Guo X; Cheng C; Wei X
Front Biosci (Landmark Ed); 2023 Sep; 28(9):195. PubMed ID: 37796705
[TBL] [Abstract][Full Text] [Related]
10. A novel Mcl-1 inhibitor synergizes with venetoclax to induce apoptosis in cancer cells.
Zhao T; He Q; Xie S; Zhan H; Jiang C; Lin S; Liu F; Wang C; Chen G; Zeng H
Mol Med; 2023 Jan; 29(1):10. PubMed ID: 36658493
[TBL] [Abstract][Full Text] [Related]
11. Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation.
Peris I; Romero-Murillo S; Martínez-Balsalobre E; Farrington CC; Arriazu E; Marcotegui N; Jiménez-Muñoz M; Alburquerque-Prieto C; Torres-López A; Fresquet V; Martínez-Climent JA; Mateos MC; Cayuela ML; Narla G; Odero MD; Vicente C
Blood; 2023 Mar; 141(9):1047-1059. PubMed ID: 36455198
[TBL] [Abstract][Full Text] [Related]
12. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
[TBL] [Abstract][Full Text] [Related]
13. Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Hormi M; Birsen R; Belhadj M; Huynh T; Cantero Aguilar L; Grignano E; Haddaoui L; Guillonneau F; Mayeux P; Hunault M; Tamburini J; Kosmider O; Fontenay M; Bouscary D; Chapuis N
Eur J Haematol; 2020 Nov; 105(5):588-596. PubMed ID: 32659848
[TBL] [Abstract][Full Text] [Related]
14. Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations.
Larrue C; Saland E; Vergez F; Serhan N; Delabesse E; Mansat-De Mas V; Hospital MA; Tamburini J; Manenti S; Sarry JE; Récher C
Mol Cancer Ther; 2015 Oct; 14(10):2364-73. PubMed ID: 26206337
[TBL] [Abstract][Full Text] [Related]
15. Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells.
Fiskus W; Cai T; DiNardo CD; Kornblau SM; Borthakur G; Kadia TM; Pemmaraju N; Bose P; Masarova L; Rajapakshe K; Perera D; Coarfa C; Mill CP; Saenz DT; Saenz DN; Sun B; Khoury JD; Shen Y; Konopleva M; Bhalla KN
Blood Cancer J; 2019 Jan; 9(2):4. PubMed ID: 30647404
[TBL] [Abstract][Full Text] [Related]
16. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of mitochondrial translation overcomes venetoclax resistance in AML through activation of the integrated stress response.
Sharon D; Cathelin S; Mirali S; Di Trani JM; Yanofsky DJ; Keon KA; Rubinstein JL; Schimmer AD; Ketela T; Chan SM
Sci Transl Med; 2019 Oct; 11(516):. PubMed ID: 31666400
[TBL] [Abstract][Full Text] [Related]
18. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
19. Targeting Mitochondrial Structure Sensitizes Acute Myeloid Leukemia to Venetoclax Treatment.
Chen X; Glytsou C; Zhou H; Narang S; Reyna DE; Lopez A; Sakellaropoulos T; Gong Y; Kloetgen A; Yap YS; Wang E; Gavathiotis E; Tsirigos A; Tibes R; Aifantis I
Cancer Discov; 2019 Jul; 9(7):890-909. PubMed ID: 31048321
[TBL] [Abstract][Full Text] [Related]
20. Abivertinib synergistically strengthens the anti-leukemia activity of venetoclax in acute myeloid leukemia in a BTK-dependent manner.
Huang S; Li C; Zhang X; Pan J; Li F; Lv Y; Huang J; Ling Q; Ye W; Mao S; Huang X; Jin J
Mol Oncol; 2020 Oct; 14(10):2560-2573. PubMed ID: 32519423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]